The HDL particle composition determines its antitumor activity in pancreatic cancer

Author:

Oberle Raimund1ORCID,Kührer Kristina1,Österreicher Tamina1,Weber Florian2ORCID,Steinbauer Stefanie3ORCID,Udonta Florian4,Wroblewski Mark4,Ben-Batalla Isabel5,Hassl Ingrid1,Körbelin Jakob6ORCID,Unseld Matthias7,Jauhiainen Matti8,Plochberger Birgit2,Röhrl Clemens3ORCID,Hengstschläger Markus1,Loges Sonja9ORCID,Stangl Herbert1ORCID

Affiliation:

1. Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria

2. School of Medical Engineering and Applied Social Sciences, University of Applied Sciences Upper Austria, Linz, Austria

3. Center of Excellence Food Technology and Nutrition, University of Applied Sciences Upper Austria, Wels, Austria

4. Department of Oncology, Hematology and Bone Marrow Transplantation, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

5. Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany

6. ENDomics Lab, Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

7. Department of Medicine I, Division of Palliative Medicine, Medical University of Vienna, Vienna, Austria

8. Minerva Foundation Institute for Medical Research and Finnish Institute for Health and Welfare, Genomics and Biobank Unit, Biomedicum 2U, Helsinki, Finland

9. Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

Abstract

Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous research identified lipid metabolic pathways to be highly enriched in pancreatic ductal adenocarcinoma (PDAC) cells. Thereby, cholesterol uptake and synthesis promotes growth advantage to and chemotherapy resistance for PDAC tumor cells. Here, we demonstrate that high-density lipoprotein (HDL)–mediated efficient cholesterol removal from cancer cells results in PDAC cell growth reduction and induction of apoptosis in vitro. This effect is driven by an HDL particle composition–dependent interaction with SR-B1 and ABCA1 on cancer cells. AAV-mediated overexpression of APOA1 and rHDL injections decreased PDAC tumor development in vivo. Interestingly, plasma samples from pancreatic-cancer patients displayed a significantly reduced APOA1-to-SAA1 ratio and a reduced cholesterol efflux capacity compared with healthy donors. We conclude that efficient, HDL-mediated cholesterol depletion represents an interesting strategy to interfere with the aggressive growth characteristics of PDAC.

Funder

Medical Faculty of the University of Hamburg

European Research Council

Hector Foundation II

Austrian Science Fund

Erwin-Schrödinger Fellowship of the Austrian Science

Publisher

Life Science Alliance, LLC

Subject

Health, Toxicology and Mutagenesis,Plant Science,Biochemistry, Genetics and Molecular Biology (miscellaneous),Ecology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3